SCI Pharmtech, Inc. (TPE:4119)

Market Cap	6.30B -39.2%
Revenue (ttm)	1.34B -11.8%
Net Income	107.37M -79.9%
EPS	0.90 -79.8%
Shares Out	119.51M
PE Ratio	58.56
Forward PE	n/a
Dividend	1.50 (2.87%)
Ex-Dividend Date	Jul 1, 2025

Volume	70,658
Average Volume	187,774
Open	52.90
Previous Close	52.30
Day's Range	52.20 - 52.90
52-Week Range	46.85 - 83.70
Beta	0.13
RSI	49.78
Earnings Date	Mar 18, 2026

About SCI Pharmtech

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychloroquine sulfate, loxoprofen sodium, methylphenidate HCl, pentobarbital sodium, pimobendan, probucol, propafenone HCI, sodium valproate, thiopental, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 245
• Stock Exchange: Taiwan Stock Exchange
• Ticker Symbol: 4119

Financial Performance

In 2025, SCI Pharmtech's revenue was 1.34 billion, a decrease of -11.81% compared to the previous year's 1.52 billion. Earnings were 107.37 million, a decrease of -79.92%.